Evidence map›Paper›PMID 34232334›Full record

ArticleNeuroradiology2021

MRI evidence of extraocular muscle atrophy and fatty replacement in myasthenia gravis.

Georgios Velonakis, Vassilis E Papadopoulos, Efstratios Karavasilis, Dimitrios K Filippiadis, Vasiliki Zouvelou

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 18 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Sarcopenia and nervous system disorders.Journal of neurology · 2022
    Review
  6. Article
  7. Review
  8. Extraocular Muscle Atrophy in Myasthenia Gravis.Annals of Indian Academy of Neurology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Georgios Velonakis2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-0050-284X
Vassilis E Papadopoulos1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, 74 Vas. Sophias Ave., 11528, Athens, Greece.ORCID http://orcid.org/0000-0001-8772-5896
Efstratios Karavasilis2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-7291-2231
Dimitrios K Filippiadis2nd Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0002-1424-7464
Vasiliki Zouvelou1st Department of Neurology, School of Medicine, National and Kapodistrian University of Athens, Eginition Hospital, 74 Vas. Sophias Ave., 11528, Athens, Greece. vzouvelu@med.uoa.gr.ORCID http://orcid.org/0000-0002-4652-3582
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the study was to evaluate extraocular muscle (EOM) atrophy and fatty replacement in ocular myasthenia gravis (OMG) and generalized myasthenia gravis (GMG) patients with chronic and untreated ocular symptoms or with inadequate response to immunotherapy and unprovoked ocular exacerbations despite chronic immunotherapy.

methodsNineteen patients with either OMG or GMG and 19 healthy age-matched controls underwent an orbital MRI. Visually obvious muscle atrophy and muscle fatty replacement were evaluated by two raters independently. Maximum thickness of EOM was measured. Measurements of the muscles of each participant were added up, in order to calculate the total thickness.

resultsEleven patients suffered from AChR-positive GMG, and 8 patients from OMG. All patients had chronic ocular symptoms or inadequate response to corticosteroids and unprovoked ocular exacerbations in spite of immunotherapy. Fatty replacement was reported in 6/19 (31.6%) patients and 0/19 (0%) controls (p = 0.02). Obvious atrophy in at least one muscle was reported in 8/19 (42.1%) patients and 1/19 (5.3%) controls (p = 0.019). Statistically significant differences between the two groups were also found in the mean total thickness, as well as in the thickness of superior recti, levator palpebrae, inferior recti, and superior oblique muscles.

conclusionEOM atrophy and fatty replacement were seen frequently in our series of MG patients with treatment difficulties and frequent relapses of ocular involvement.

Indexed as

Myasthenia GravisOculomotor MusclesAtrophyHumansMagnetic Resonance ImagingNeoplasm Recurrence, LocalAtrophyExtraocular musclesFatty replacementMyasthenia gravisOrbital MRI

Identifiers

PMID34232334
OpenAlexW3182807865

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.